- Article
Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia
- Javier Bregante,
- Anna Schönbichler,
- Daniel Pölöske,
- Lina Degenfeld-Schonburg,
- Garazi Monzó Contreras,
- Emir Hadzijusufovic,
- Elvin D. de Araujo,
- Peter Valent,
- Richard Moriggl and
- Anna Orlova
Constitutive activation of FLT3 by ITD mutations is one of the most common genetic aberrations in AML, present in ~1/3 of cases. Patients harboring FLT3-ITD display worse clinical outcomes. The integration and advancement of FLT3 TKI in AML treatment...